15.08.2013 • NewsBever PharmaceuticalPharmstandard

Pharmstandard to Buy Ingredient Supplier for $590 Million

Russian drugmaker Pharmstandard has agreed to buy a supplier of ingredients for its flagship anti-viral and anxiety drugs for $590 million, as part of a plan to spin off its over-the-counter (OTC) business.

The plan to purchase Bever Pharmaceutical prompted a sell-off in Pharmstandard's shares when it was first announced in July. Analysts were concerned about a lack of information regarding Bever or a clear reason for the deal.

Pharmstandard said it would pay $542 million in shares and $48 million in cash to buy Bever from Pharmstandard board member Alexander Shuster, who will become Pharmstandard's second-largest shareholder with an 18.7% stake.

The deal was initially valued at $630 million. Pharmstandard has said Bever would become part of the OTC unit it plans to spin off and later list on the Moscow Exchange.

With a market value of around $2 billion, Pharmstandard is Russia's biggest drug maker in a market dominated by foreign pharmaceutical firms.

It said in a statement that the deal aimed to secure the long-term supply of critical pharmaceutical ingredients for its antiviral drug Arbidol and anti-anxiety drug Aphobazolum and to improve profitability after securing lower prices.

In a presentation on its website, Pharmstandard said Bever signed on June 25 a new 20-year contract for the supplies of the ingredients at a fixed price, adding Pharmstandard could have saved $60 million had it been signed in 2012.

The company also said on a conference call it would continue to develop the prescription business as well as sales of third-party drugs after the completion of the proposed OTC spin-off and was open to more acquisition opportunities.

Pharmstandard recently bought Shuster's 5.4% stake in Pharmstandard subsidiary Donelle, which has the rights to Aphobazolum, for 121 million rubles, and plans to buy out the remaining 5.47% it does not already own from third parties. 

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.